Terms: = Breast cancer AND BCL9, LGS, 607, ENSG00000116128, MGC131591 AND Prognosis
17 results:
1. Development and validation of a nomogram for predicting lymph node metastasis in ductal carcinoma in situ with microinvasion: A SEER population-based study.
Zhu K; Sui Y; Zhu M; Gao Y; Yuan Y; Sun P; Meng L; Dai J; Li Z
PLoS One; 2024; 19(4):e0301057. PubMed ID: 38557552
[TBL] [Abstract] [Full Text] [Related]
2. Association Between a History of breast cancer and Decreased Thyroid cancer-specific Mortality.
Lin S; Wang Z; Xing M
J Clin Endocrinol Metab; 2024 Apr; 109(5):1222-1230. PubMed ID: 38064679
[TBL] [Abstract] [Full Text] [Related]
3. Zinc finger and SCAN domain-containing protein 18 is a potential DNA methylation-modified tumor suppressor and biomarker in breast cancer.
Wang Y; Luo Y; Fu S; He L; Pan G; Fan D; Wen Q; Fan Y
Front Endocrinol (Lausanne); 2023; 14():1095604. PubMed ID: 37223020
[TBL] [Abstract] [Full Text] [Related]
4. New Biomarkers Based on Dendritic Cells for breast cancer Treatment and prognosis Diagnosis.
Zhao F; Yan F; Liu H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835467
[TBL] [Abstract] [Full Text] [Related]
5. RT-induced dynamic changes in the lymphocyte-to-monocyte ratio in patients with breast cancer indicate poor prognosis.
Kim D; Bae SJ; Ahn SG; Jeong J; Park S; Park WC; Park G; Lee S; Yoon CI
Breast Cancer Res Treat; 2022 Jun; 193(3):637-647. PubMed ID: 35426542
[TBL] [Abstract] [Full Text] [Related]
6. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
[No Abstract] [Full Text] [Related]
7. Impact of an In Situ Component on Outcome After In-breast Tumor Recurrence in Patients Treated with breast-Conserving Therapy.
Laird J; Lok B; Siu C; Cahlon O; Khan AJ; McCormick B; Powell SN; Cody H; Wen HY; Ho A; Braunstein LZ
Ann Surg Oncol; 2018 Jan; 25(1):154-163. PubMed ID: 29094250
[TBL] [Abstract] [Full Text] [Related]
8. Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function.
Hauck PM; Wolf ER; Olivos DJ; Batuello CN; McElyea KC; McAtarsney CP; Cournoyer RM; Sandusky GE; Mayo LD
Mol Cancer Res; 2017 Nov; 15(11):1598-1607. PubMed ID: 28784612
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract] [Full Text] [Related]
10. Mammographic density as a predictor of breast cancer survival: the Multiethnic Cohort.
Maskarinec G; Pagano IS; Little MA; Conroy SM; Park SY; Kolonel LN
Breast Cancer Res; 2013 Jan; 15(1):R7. PubMed ID: 23339436
[TBL] [Abstract] [Full Text] [Related]
11. Mind the gap: racial differences in breast cancer incidence and biologic phenotype, but not stage, among low-income women participating in a government-funded screening program.
Cunningham JE; Walters CA; Hill EG; Ford ME; Barker-Elamin T; Bennett CL
Breast Cancer Res Treat; 2013 Jan; 137(2):589-98. PubMed ID: 23239148
[TBL] [Abstract] [Full Text] [Related]
12. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response.
Godoy P; Cadenas C; Hellwig B; Marchan R; Stewart J; Reif R; Lohr M; Gehrmann M; Rahnenführer J; Schmidt M; Hengstler JG
Breast Cancer; 2014 Jul; 21(4):491-9. PubMed ID: 23001506
[TBL] [Abstract] [Full Text] [Related]
13. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
[TBL] [Abstract] [Full Text] [Related]
14. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract] [Full Text] [Related]
15. Estrogen replacement therapy after breast cancer: a 12-year follow-up.
Peters GN; Fodera T; Sabol J; Jones S; Euhus D
Ann Surg Oncol; 2001 Dec; 8(10):828-32. PubMed ID: 11776498
[TBL] [Abstract] [Full Text] [Related]
16. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity.
Michels JJ; Duigou F; Marnay J
Breast Cancer Res Treat; 2000 Jul; 62(2):117-26. PubMed ID: 11016749
[TBL] [Abstract] [Full Text] [Related]
17. Factors at presentation influencing the prognosis in breast cancer.
Caleffi M; Fentiman IS; Birkhead BG
Eur J Cancer Clin Oncol; 1989 Jan; 25(1):51-6. PubMed ID: 2920768
[TBL] [Abstract] [Full Text] [Related]
